Charles Schwab Investment Management Inc. Sells 934,497 Shares of Emergent BioSolutions Inc. (NYSE:EBS)

Charles Schwab Investment Management Inc. lessened its holdings in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 42.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,290,230 shares of the biopharmaceutical company's stock after selling 934,497 shares during the period. Charles Schwab Investment Management Inc. owned 2.38% of Emergent BioSolutions worth $12,335,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Jacobs Levy Equity Management Inc. acquired a new position in Emergent BioSolutions in the 3rd quarter worth $1,547,000. Oak Hill Advisors LP acquired a new stake in Emergent BioSolutions in the 3rd quarter valued at $9,296,000. Barclays PLC lifted its position in Emergent BioSolutions by 361.6% during the 3rd quarter. Barclays PLC now owns 39,308 shares of the biopharmaceutical company's stock worth $329,000 after buying an additional 30,792 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Emergent BioSolutions by 4.6% in the third quarter. Geode Capital Management LLC now owns 581,958 shares of the biopharmaceutical company's stock valued at $4,861,000 after acquiring an additional 25,776 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its position in Emergent BioSolutions by 41.7% during the fourth quarter. New York State Common Retirement Fund now owns 306,286 shares of the biopharmaceutical company's stock valued at $2,928,000 after purchasing an additional 90,113 shares during the last quarter. Institutional investors and hedge funds own 78.40% of the company's stock.

Remove Ads

Emergent BioSolutions Stock Down 4.2 %

NYSE EBS traded down $0.24 on Tuesday, hitting $5.49. 838,222 shares of the company were exchanged, compared to its average volume of 2,611,695. Emergent BioSolutions Inc. has a 12 month low of $1.82 and a 12 month high of $15.10. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The company has a market cap of $298.31 million, a PE ratio of -1.34 and a beta of 1.80. The stock has a fifty day moving average of $8.41 and a 200-day moving average of $8.72.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.40. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. The firm had revenue of $194.70 million for the quarter, compared to analyst estimates of $254.67 million. During the same period last year, the firm earned ($0.77) earnings per share. As a group, analysts forecast that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Neal Franklin Fowler sold 35,000 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total value of $204,050.00. Following the completion of the sale, the director now directly owns 101,100 shares of the company's stock, valued at approximately $589,413. This represents a 25.72 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.20% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on EBS. HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of Emergent BioSolutions in a research note on Friday. StockNews.com downgraded Emergent BioSolutions from a "buy" rating to a "hold" rating in a research report on Wednesday, March 5th.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.